The Serum Levels of Asymmetric Dimethylarginine, Vascular Endothelial Growth Factor, and Insulin-Like Growth Factor-1 in Preterms with Retinopathy of Prematurity

• Published in: Fetal and pediatric pathology 2022-07, Vol.41 (4), p.634-639
• Main Authors: Aydoğan, Seda, Dilli, Dilek, Kabataş, Emrah Utku, Akduman, Hasan, Şah Ipek, Mehmet, Oğuz, Baran, Ataş, Nurgül, Zenciroğlu, Ayşegül
• Format: Article
• Language: English
• Subjects: Asymmetric dimethylarginine; insulin-like growth factor-1; retinopathy of prematurity; vascular endothelial growth factor
• ISSN: 1551-3815; 1551-3823
• DOI: 10.1080/15513815.2021.1948644

Objective:To determine the serum levels of asymmetric dimethylarginine (ADMA), vascular endothelial growth factor (VEGF), and insulin-like growth factor-1 (IGF-1) in preterms with retinopathy of prematurity (ROP). Materials and Methods: We included 37 preterm infants. The first blood samples were obtained within the first 5 days of life and repeated at the time of the first ophthalmologic examination for ROP. The levels of ADMA, IGF-1, and VEGF were measured in all samples. Results: ROP was detected in 12 of the subjects (32.4%). We categorized the subjects as non-ROP (Group 1; n = 25), untreated ROP (Group 2; n = 7), and treated ROP (Group 3; n = 5) according to the eye findings. There were no significant differences among the groups for serum levels of ADMA, VEGF, and IGF-1 at the first sampling. Conclusion: We did not find any differences in terms of serum ADMA, IGF-1, and VEGF levels in preterm infants with or without ROP.